This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
Login or create an account to see restricted content
Login or RegisterThe observation that some traditional classes of glucose-lowering agents may have contributed to elevated CV risk prompted regulatory agencies to mandate that new diabetes drugs demonstrate CV safety in dedicated, long-term, placebo controlled CV outcome trials. Evidence from some recent cardiovascular outcome trials has shown improved CV outcomes over and above existing therapies for CV risk factor control.
Overview of heart failure information in patients with T2D and data fr
This module summarises reported and ongoing GLP-1 receptor agonist CVO
The DAPA-HF trial assessed the efficacy and safety of dapagliflozin
The REWIND CVOT assessed the cardiovascular safety of dulaglutide in p
The CAROLINA trial assessed the long-term CV safety of linagliptin i
The PIONEER 6 CVOT assessed the cardiovascular safety of oral semaglut
The DECLARE-TIMI 58 CVOT assessed the cardiovascular safety of dapagli
This module summarises reported DPP-4 inhibitor CVOTs for saxagliptin
Evaluating the CV and kidney safety profile of linagliptin versus
The Harmony Outcomes CVOT assessed the cardiovascular safety of albi
The SAVOR-TIMI 53 CVOT assessed the cardiovascular effect of saxaglipt
The EXAMINE CVOT assessed the cardiovascular safety of alogliptin in p
The TECOS CVOT assessed the cardiovascular safety of sitagliptin in pa
The CREDENCE cardio-renal outcomes trial investigated the effect of ca
The LEADER trial assessed the CV safety of liraglutide versus placebo
Addendum to EMPA-REG OUTCOME® presenting detailed analysis
The EXSCEL trial assessed the CV safety of once weekly exenatide versu
The ELIXA trial assessed CV safety associated with lixisenatide versus
SUSTAIN-6 was designed as a non-inferiority trial to assess the CV saf
This module outlines CVOTs for empagliflozin (EMPA-REG OUTCOME®
Renal findings from the EMPA-REG OUTCOME® trial
